Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market

Subcutaneous Lunsumio + Polivy (VELO) accounts for 41.4% of the therapy regimen segment. Second-line therapy leads line of therapy with 45.7%, while hospitals hold 41.3% of end-user share. Subcutaneous administration dominates the route of administration segment with a 67.5% share.